Targeted Molecule Therapeutics and the Role of Cytokines in Oncological Treatment with John Mulligan

Is there a better answer coming to oncology therapeutics? Using targeted molecule therapies, a broader base of patients may be found. Press play to learn:

• How John Mulligan came to Good Therapeutics
• The impact of tumor-specific T-cells
• Other cytokines that can be effective treatments

John Mulligan, the CEO at Good Therapeutics, shares his work developing targeted molecular therapies for a variety of applications.

Genetics can be a surprisingly strong tool in modeling and developing a novel drug. However, the applications can be fairly limited since the patient base can be only a percentage of folks compared to other traditional therapeutics.

One of the most promising new developments is the use of Cytokines to treat and combat many forms of cancer. The hope is to expand the application to a broader base of patients moving forward. 

Visit https://goodtherapeutics.com for more information.

Episode also available on Apple Podcast: http://apple.co/30PvU9C